Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
WEST LAFAYETTE, Ind., May 25, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research...
WEST LAFAYETTE, Ind., May 19, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug d...
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
In Vivo Services
Histology
Pathology
DMPK
Consulting
Research Models
Research Model Services
Teklad Diet and Bedding
